Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.

Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N, Springer CJ, Powles T, Nathan PD, Larkin J, Gore M, Vasudev NS, Reynolds AR.

Mol Cancer Ther. 2016 Jan;15(1):172-83. doi: 10.1158/1535-7163.MCT-15-0170. Epub 2015 Oct 20.

2.

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.

Diaz-Montero CM, Mao FJ, Barnard J, Parker Y, Zamanian-Daryoush M, Pink JJ, Finke JH, Rini BI, Lindner DJ.

Br J Cancer. 2016 Oct 11;115(8):920-928. doi: 10.1038/bjc.2016.263. Epub 2016 Aug 25.

3.

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R.

Mol Cancer Ther. 2010 Jun;9(6):1525-35. doi: 10.1158/1535-7163.MCT-09-1106. Epub 2010 May 25.

4.

Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.

Gao Y, Li J, Qiao N, Meng Q, Zhang M, Wang X, Jia J, Yang S, Qu C, Li W, Wang D.

Oncotarget. 2016 Sep 27;7(39):63374-63387. doi: 10.18632/oncotarget.11463.

5.

Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.

Su SC, Hu X, Kenney PA, Merrill MM, Babaian KN, Zhang XY, Maity T, Yang SF, Lin X, Wood CG.

Clin Cancer Res. 2013 Dec 1;19(23):6461-72. doi: 10.1158/1078-0432.CCR-13-1284. Epub 2013 Oct 11.

6.

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.

Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H.

Cancer Res. 2009 Mar 15;69(6):2506-13. doi: 10.1158/0008-5472.CAN-08-4323. Epub 2009 Feb 24.

7.

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.

Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E.

Oncogene. 2016 May;35(21):2687-97. doi: 10.1038/onc.2015.343. Epub 2015 Sep 14.

8.

The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.

Grépin R, Ambrosetti D, Marsaud A, Gastaud L, Amiel J, Pedeutour F, Pagès G.

PLoS One. 2014 Mar 27;9(3):e89449. doi: 10.1371/journal.pone.0089449. eCollection 2014.

9.

Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.

Martin B, Edeline J, Patard JJ, Oger E, Jouan F, Boulanger G, Zerrouki S, Vigneau C, Rioux-Leclercq N.

J Cancer Res Clin Oncol. 2012 Jun;138(6):907-16. doi: 10.1007/s00432-012-1162-x. Epub 2012 Feb 10.

PMID:
22322364
10.

Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.

Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G.

Br J Cancer. 2013 Aug 6;109(3):686-93. doi: 10.1038/bjc.2013.360. Epub 2013 Jul 9.

11.

Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

Radulovic S, Bjelogrlic SK.

J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.

PMID:
17935273
12.

Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.

Han KS, Raven PA, Frees S, Gust K, Fazli L, Ettinger S, Hong SJ, Kollmannsberger C, Gleave ME, So AI.

Neoplasia. 2015 Nov;17(11):805-16. doi: 10.1016/j.neo.2015.11.001.

13.

A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.

Stubbs C, Bardoli AD, Afshar M, Pirrie S, Miscoria M, Wheeley I, Porfiri E.

Anticancer Res. 2017 Jan;37(1):253-259.

PMID:
28011500
14.

Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.

Tran TA, Leong HS, Pavia-Jimenez A, Fedyshyn S, Yang J, Kucejova B, Sivanand S, Spence P, Xie XJ, Peña-Llopis S, Power N, Brugarolas J.

Mol Cell Biol. 2016 Jun 15;36(13):1836-55. doi: 10.1128/MCB.00189-16. Print 2016 Jul 1.

15.

HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.

Lai XM, Liu SY, Tsai YT, Sun GH, Chang SY, Huang SM, Cha TL.

Oncotarget. 2017 Jul 25;8(30):49713-49724. doi: 10.18632/oncotarget.17923.

16.

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.

Cancer Res. 2010 Feb 1;70(3):1053-62. doi: 10.1158/0008-5472.CAN-09-3722. Epub 2010 Jan 26.

17.

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS.

Clin Cancer Res. 2015 Apr 15;21(8):1925-1934. doi: 10.1158/1078-0432.CCR-14-2031. Epub 2015 Jan 14.

18.

Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.

Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP.

Int J Cancer. 2012 Jun 1;130(11):2693-702. doi: 10.1002/ijc.26303. Epub 2011 Sep 14.

19.

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.

20.

Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.

Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, Talamini L, Fiordaliso F, Bisighini C, Damia G, Bani MR, Piccirillo R, Giavazzi R.

Oncotarget. 2015 Feb 20;6(5):3043-54. Erratum in: Oncotarget. 2016 Jun 21;7(25):38973.

Supplemental Content

Support Center